ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,039.31
      -0.47%
      US Tech 100
      20,916.00
      0.40%
      Dow Jones
      44,713.52
      -0.31%
      Brent Oil
      75.405
      -0.68%
      Bitcoin
      105,205.86
      1.42%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Kiniksa Pharmaceuticals International PLC (KNSA) Quote

      Kiniksa Pharmaceuticals International PLC

      Kiniksa Pharmaceuticals International PLC (KNSA)

      NASDAQ
      20.66
      0.48
      (2.38%)
      Closed January 29 4:00PM
      Delayed by 15 minutes
      18.00
      -2.66
      ( -12.88% )
      Pre Market: 4:50AM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      18.00
      Bid
      17.61
      Ask
      33.05
      Volume
      231
      0.00 Day's Range 0.00
      16.56 52 Week Range 28.15
      Market Cap
      1.3B
      Previous Close
      20.66
      Open
      -
      Last Trade
      1
      @
      18.01
      Last Trade Time
      04:48:51
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      398,776
      Shares Outstanding
      72,201,565
      Dividend Yield
      -
      PE Ratio
      105.89
      Earnings Per Share (EPS)
      0.2
      Revenue
      270.26M
      Net Profit
      14.08M

      About Kiniksa Pharmaceuticals International PLC

      Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurre... Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.kiniksa.com
      Headquarters
      London, Gbr
      Founded
      -
      Kiniksa Pharmaceuticals International PLC is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker KNSA. The last closing price for Kiniksa Pharmaceuticals was $20.66. Over the last year, Kiniksa Pharmaceuticals shares have traded in a share price range of $ 16.56 to $ 28.15.

      Kiniksa Pharmaceuticals currently has 72,201,565 shares outstanding. The market capitalization of Kiniksa Pharmaceuticals is $1.49 billion. Kiniksa Pharmaceuticals has a price to earnings ratio (PE ratio) of 105.89.

      Ask ADVFN Intelligence (AI)

      Kiniksa Pharmaceuticals (KNSA) Options Flow Summary

      KNSA Options Flow

      Overall Flow

      Bearish

      Net Premium

      -21k

      Calls / Puts

      100.00%

      Buys / Sells

      0.00%

      OTM / ITM

      100.00%

      Sweeps Ratio

      0.00%

      KNSA Latest News

      More News

      Form 4 - Statement of changes in beneficial ownership of securities

      January 15 2025
      Edgar (US Regulatory)

      Form 144 - Report of proposed sale of securities

      January 13 2025
      Edgar (US Regulatory)

      Form 8-K - Current report

      January 13 2025
      Edgar (US Regulatory)

      Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance

      – ARCALYST® (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-over-year growth –– ARCALYST 2025 net product revenue expected to be $560 - $580 million ––...

      January 13 2025
      GlobeNewswire Inc.

      Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

      LONDON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on...

      January 06 2025
      GlobeNewswire Inc.

      Form 4 - Statement of changes in beneficial ownership of securities

      December 18 2024
      Edgar (US Regulatory)

      Form 144 - Report of proposed sale of securities

      December 16 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      December 10 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      December 05 2024
      Edgar (US Regulatory)

      Form 144 - Report of proposed sale of securities

      December 03 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-1.76-8.9068825910919.7621.371877237120.39690393CS
      4-2-102021.3717.8257946719.56311152CS
      12-5-21.73913043482323.51517.8239877620.37242725CS
      26-8.3-31.558935361226.328.1517.8238590923.05468932CS
      52-0.39-2.120717781418.3928.1516.5640124521.5837672CS
      1567.0364.083865086610.9728.157.3639061816.64879141CS
      26032015337.3639200016.6536204CS

      KNSA - Frequently Asked Questions (FAQ)

      What is the current Kiniksa Pharmaceuticals share price?
      The current share price of Kiniksa Pharmaceuticals is $ 18.00
      How many Kiniksa Pharmaceuticals shares are in issue?
      Kiniksa Pharmaceuticals has 72,201,565 shares in issue
      What is the market cap of Kiniksa Pharmaceuticals?
      The market capitalisation of Kiniksa Pharmaceuticals is USD 1.49B
      What is the 1 year trading range for Kiniksa Pharmaceuticals share price?
      Kiniksa Pharmaceuticals has traded in the range of $ 16.56 to $ 28.15 during the past year
      What is the PE ratio of Kiniksa Pharmaceuticals?
      The price to earnings ratio of Kiniksa Pharmaceuticals is 105.89
      What is the cash to sales ratio of Kiniksa Pharmaceuticals?
      The cash to sales ratio of Kiniksa Pharmaceuticals is 5.52
      What is the reporting currency for Kiniksa Pharmaceuticals?
      Kiniksa Pharmaceuticals reports financial results in USD
      What is the latest annual turnover for Kiniksa Pharmaceuticals?
      The latest annual turnover of Kiniksa Pharmaceuticals is USD 270.26M
      What is the latest annual profit for Kiniksa Pharmaceuticals?
      The latest annual profit of Kiniksa Pharmaceuticals is USD 14.08M
      What is the registered address of Kiniksa Pharmaceuticals?
      The registered address for Kiniksa Pharmaceuticals is THIRD FLOOR, 23 OLD BOND STREET, LONDON, W1S 4PZ
      What is the Kiniksa Pharmaceuticals website address?
      The website address for Kiniksa Pharmaceuticals is www.kiniksa.com
      Which industry sector does Kiniksa Pharmaceuticals operate in?
      Kiniksa Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      ATHEAlterity Therapeutics Limited
      $ 6.07
      (108.59%)
      		1.8M
      NAOVNanoVibronix Inc
      $ 0.7317
      (90.80%)
      		15.89M
      CFSBCFSB Bancorp Inc
      $ 12.00
      (57.27%)
      		6
      GDEVGDEV Inc
      $ 24.99
      (56.29%)
      		1
      RBBRBB Bancorp
      $ 29.99
      (54.03%)
      		7
      CRGXCARGO Therapeutics Inc
      $ 3.42
      (-74.07%)
      		410.16k
      ECBKECB Bancorp Inc
      $ 8.01
      (-41.49%)
      		5
      FBLAFB Bancorp Inc
      $ 7.01
      (-40.34%)
      		7
      CEPOCantor Equity Partners I Inc
      $ 6.01
      (-40.26%)
      		1
      AURAAura Biosciences Inc
      $ 5.02
      (-36.62%)
      		11
      NAOVNanoVibronix Inc
      $ 0.7317
      (90.80%)
      		15.89M
      XFORX4 Pharmaceuticals Inc
      $ 0.872
      (18.61%)
      		10.05M
      MGOLMGO Global Inc
      $ 0.1282
      (26.06%)
      		7.95M
      TSLLDirexion Daily TSLA Bull 2X Trust ETF
      $ 25.65
      (3.72%)
      		2.5M
      ATHEAlterity Therapeutics Limited
      $ 6.07
      (108.59%)
      		1.8M

      KNSA Discussion

      View Posts
      Monksdream Monksdream 4 months ago
      KNSA inching back up
      👍️0
      DonDonDonDon DonDonDonDon 4 years ago
      No bueno. I guess HGEN's lenzilumab is the best of the anti-GM-CSF drugs for Covid. Lenzilumab's trial showed 54% efficacy. It is guaranteed an EUA within a couple of weeks yet its stock is 20% below where it was a month ago. It dropped 2 days ago because they diluted 5 million shares to pay for manufacturing.

      https://www.rheumatologyadvisor.com/home/general-rheumatology/mavrilimumab-outcomes-patients-with-severe-covid19-pneumonia-hyperinflammation/
      👍️0
      DonDonDonDon DonDonDonDon 4 years ago
      It was recently discovered that the protein GM-CSF is the cytokine responsible for severe Covid and death. Kiniksa will surely get a government grant to do an additional trial. Here is a BBC article about the trial that determined that GM-CSF is key to Covid:

      https://www.bbc.com/news/health-56352128

      Here is an additional article stating that KNSA and HGEN are the two companies with the best GM-CSF drugs to combat Covid:

      https://www.clinicaltrialsarena.com/comment/humanigens-and-kiniksas-anti-gm-csf-antibodies-likely-to-garner-a-place-for-nonventilated-covid-19-patients/
      👍️0
      Femto99 Femto99 4 years ago
      PT= $30-40 (by or around March 31st)
      https://msmoneymoves.com/2021/02/17/knsa-report/
      👍️0
      Femto99 Femto99 4 years ago
      PDUFA Mar21
      👍️0

      Your Recent History

      NASDAQ
      KNSA
      Kiniksa Pharmaceuticals
      BIT
      T00007
      Banca Cesare Ponti
      BIT
      UC80KT
      Unicredit Bank
      BIT
      S27201
      Societe Generale Effekten
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads